Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 26 years of covering Asia Pacific equities, the past 20 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>On the 17th July 2026 , <strong><a href="https://www.smartkarma.com/entities/jbm-healthcare-ltd-ac30be57-e952-486f-bc3f-9973822a014f" target="_blank" data-smartkarma-citation="entities:49035:1" rel="noopener">JBM (Healthcare) (2161 HK)</a></strong>, a consumer healthcare company, announced the spin-off of 100%-held JPJ, the group’s branded PCM products and Chinese medicine clinic services.</li>
<li>Listing is slated for the HKEx, market conditions permitting. An application proof has been lodged. JBM intends to hold at least 50% of JPJ post listing.</li>
<li>My calcs suggest JBM is fairly valued here - before assigning any holdco discount post spin-off. FWIW, JBM was itself spun-off from <strong><a href="https://www.smartkarma.com/entities/jacobson-pharma-corporation-limited" target="_blank" data-smartkarma-citation="entities:23579:1" rel="noopener">Jacobson Pharma (2633 HK)</a></strong> in February 2021.</li>
</ul>


On the 17th July 2026 , JBM (Healthcare) (2161 HK), a consumer healthcare company, announced the spin-off of 100%-held JPJ, the group’s branded PCM products and Chinese medicine clinic services.
Listing is slated for the HKEx, market conditions permitting. An application proof has been lodged. JBM intends to hold at least 50% of JPJ post listing.
My calcs suggest JBM is fairly valued here - before assigning any holdco discount post spin-off. FWIW, JBM was itself spun-off from Jacobson Pharma (2633 HK) in February 2021.


Limited Upside To JBM (2161 HK)'s Spin-Off